Krueppel-like factor 11 Antibodies

Krueppel-like factor 11 (KLF11)

Transcription factor (PubMed:9748269, PubMed:10207080). Activates the epsilon- and gamma-globin gene promoters and, to a much lower level, the beta-globin gene and represses promoters containing SP1-like binding inhibiting cell growth (PubMed:9748269, PubMed:10207080, PubMed:16131492).

Represses transcription of SMAD7 which enhances TGF-beta signaling (By similarity). Induces apoptosis (By similarity).

Gene Information

Human
Gene Name:	KLF11
Uniprot:	O14901
Entrez:	8462

Family

Belongs to:
Sp1 C2H2-type zinc-finger protein family

Alternative Names

FKLFFKLF1; Krueppel-like factor 11; Kruppel-like factor 11; MODY7TGFB-inducible early growth response protein 2; TIEG-2; TIEG2TGFB inducible early growth response 2; Tieg3; Transforming growth factor-beta-inducible early growth response protein 2

Molecular Weight

Mass (kDA):
55.139 kDA

Genomic Context

Human
Location:	2p25.1
Sequence:	2; NC_000002.12 (10043550..10054836)

Tissue Specificity

Ubiquitous. Higher expression in erythroid cells.

Subcellular Localizations

Nucleus.

Diseases

• Neoplasms
• Diabetes Mellitus
• Diabetes Mellitus, Non-insulin-dependent
• Malignant Neoplasms
• Cell Transformation, Neoplastic
• Sudden Infant Death Syndrome
• Uterine Fibroids
• Dysequilibrium Syndrome
• Liver Carcinoma
• Depressive Disorder
• Uterine Neoplasms
• Neoplasm Metastasis

• Carcinoma
• Hypertrophy
• Liver Neoplasms
• Neurodegenerative Disorders
• Carcinogenesis
• Pancreatic Neoplasm
• Malignant Neoplasm Of Pancreas

Interacting Proteins

• APPBP2
• TXNDC9

Pathways

• Cell Growth
• Cell Proliferation
• Methylation
• Localization
• Insulin Secretion
• Dna Methylation
• Cell Death
• Rna Interference
• Secretion
• Cell Activation
• Gene Silencing
• Chromatin Remodeling
• Regulation Of Cell Growth

• Cell Adhesion
• T Cell Activation
• Regulation Of Gene Expression
• Glucose Homeostasis
• Tissue Development
• Reverse Transcription
• Cell Cycle

PTMs

• Methylation
• Phosphorylation

• Demethylation
• Cleavage

• Acetylation

Research Areas

• Cell Cycle and Replication
• Transcription Factors and Regulators

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/KLF11

Boster Bio - Best Uses Of The KLF11 Marker

This article provides information on the KLF11 gene as well as its uses. The KLF11 gene is covered in infographics as well as genetic tests. Learn how to use KLF11 as a marker in biological studies. The public is welcome to view the results of Boster scientists' studies. They can also claim product credits for results achieved using unvalidated goods.

Information about the KLF11 gene

While the role of KLF11 is not fully understood, it is well-known it acts as a transcriptional activater in neuronal cells. KLF11 triggers transcriptional activation by binding to specific sequences in the promoter area of genes. It regulates many cell processes, including cell proliferation and differentiation as well as endocrine diseases and malignancies.

KLF11 was originally thought to be a transcriptional inhibitor. However, new studies show that this gene can activate transcription on a wide variety cells. It binds the insulin promotor to up-regulate insulin expression in beta cells. This gene may play a part in diabetes. Affected individuals are predisposed to developing the disease by a defect in KLF11 function. Contact your doctor if you have a KLF11 mutation.

The Sp1/Kruppel-like Zinc Finger transcription Factor family includes the KLF11 gene. It plays important roles in the maintenance and growth of a wide range cell types. It is responsible for regulating gene expression and promoting TGF-b's effects on cell growth. It also influences the TGF-Smads pathway and regulates gene expression. KLF11 can be overexpressed, which can lead to apoptosis.

Progesterone can regulate the expression of KLF11 within human cells. It exerts important roles in the development of breast cancer, inhibiting estrogen-dependent endometrial carcinogenesis. KLF11 is also affected by progesterone, which regulates its function, which allows it to influence cancer growth and progression. Information about KLF11 gene and its function in breast cancer will be necessary for a better understanding of the disease's pathogenesis.

In addition to its role in regulating MAO A, KLF11 is associated with mood disorders and decreased prefrontal cortex volume. It has been shown that it contributes to the development and progression MDD. It was even found in postmortem brain tissue from depressive patients. KLF11 was also associated to oxidative stress, a trait linked with depression. These findings suggest that KLF11 can be linked with depression.

Regulating KLF11's expression is done by the distal portion of the KLF11 genome. PR binds to this distal region and regulates KLF11. PR binds the distal PR-binding area. In addition, it interacts with the basal transcriptional multimeric complex to regulate the expression of KLF11.

To assess the role of PR, knockdown experiments were performed using siRNA. LSM cells were transfected using control siRNA and PR siRNA for 72 h. After that, they were exposed to RU486 at a concentration 10-6 mol/L over 1 h. These experiments revealed that DNA interaction between SRC-2 & KLF11 was detectable. LSM cells were also transfected using a nontargeting control siRNA to provide a negative control.

Gene infographics

The low-density lipoprotein (LDL-R) receptor KLF11 is a gene. These proteins are found at cell surfaces and play an important role for signal transduction and receptormediated endocytosis. They also play a role in the Reelin signaling pathway and serve as receptors for cholesterol transport protein apolipoprotein E. Boster has validated its antibodies against the KLF11 gene using various methods.

Genetic testing

A small amount of blood or tissue is used to test for genetic changes. This sample could be blood, saliva, cheek or skin cells. After the sample has been collected, it is sent to a laboratory for genetic testing. After several weeks, the results are usually returned to your doctor. Many genetic counseling and testing is covered by insurance. Before you undergo any genetic testing, make sure to discuss the costs and benefits with your healthcare provider. Genetic testing has both risks and rewards.

There is uncertainty about the KLF11 genetic test results. The results of this test could be misleading or not informative. Worse, you may have to make decisions about your health care based on incomplete information. Genetic testing with KLF11 is not a guarantee of a specific disease. However, it can help make informed decisions about your care. Genetic testing can provide important information to loved ones that can help them make informed health decisions.

MODY is a subtype that is rare, making diagnosis difficult. Patients with this subtype usually have an autosomal dominating inheritance pattern, a family history and lack of insulin resistance. A family with three members carrying the KLF11 gene had one person with diabetes. His maternal grandfather, who was 66 years old, developed type 2 diabetes.

The KLF11 genome is a novel transcriptional regulator of F3 found in vascular smooth-muscle cells. It may be an important molecular target for inhibiting arterial thrombosis. Many cardiovascular diseases, including hypertension and atherosclerosis, are characterized by thrombosis. A ruptured plaque atherosclerotic causes platelet recruitment, which in turn leads to thrombus formation.

KLF11 can be linked to inherited cancer susceptibility and other diseases. Genetic counseling will help patients understand their risk for cancer and provide information about preventive care. Counseling can include providing emotional support and referring patients to support groups. These services can help patients deal with the emotional effects of the results. This type is useful for patients with a family history or cancer.

Diabetes can be caused through mutations in KLF11. The mutation disrupts the activity of the insulin promoter. This gene was previously associated to cystic fibrosis. Mutations in this gene result in KLF11 not binding to the promoter of the INS. This mutation results is impaired insulin synthesis by pancreatic beta-cells. MODY7 is also associated with the KLF11 gene.